Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

Clinical trial NCT05129241 · COMPLETED

Trial details

NCT number: NCT05129241
Sponsor: Sanofi
Status: COMPLETED
Study type: OBSERVATIONAL

Primary Hypercholesterolaemia and Mixed Dyslipidaemia Atherosclerotic Cardiovascular Disease

Start date: 2021-11-18
Primary completion: 2023-02-16
Enrollment: 163

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.